Clinical Trial Update: Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma [Phase 2]

View source ↗

Summary

Phase II study evaluating a PD-1 inhibitor in combination with apatinib and mitotane for advanced adrenocortical carcinoma; the trial is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Mitotane (mitotane)
• PD-1 inhibitor (unspecified)

Snippet

Sponsor: West China Hospital | Conditions: Adrenal Cortical Carcinoma, Adrenal Cortical Cancer | Phase 2 | Status: RECRUITING